Physician profile
Michael S Honor
NPI 1831196161
$14,511.31
in general payments reported to CMS, 2019-2025
55 companies · $3,768 in 2025
The $3,768 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,865 · 2020: $470 · 2021: $585 · 2022: $2,101 · 2023: $2,597 · 2024: $3,125 · 2025: $3,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,490.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,685.18 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,483.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,372.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,291.74 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Novo Nordisk INC | $995.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $879.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $860.84 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $766.68 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $442.68 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.03 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $403.09 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $366.56 | 2019-2025 | Evenity, Prolia, Otezla |
| Amarin Pharma, INC. | $362.56 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $293.18 | 2022-2025 | Eliquis |
| Exact Sciences Corporation | $284.47 | 2023-2025 | Cologuard Collection Kit |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Honor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.